AOBiome reports Phase IIb data of ammonia-oxidizing bacteria candidate for acne

AOBiome LLC (Cambridge, Mass.) said topical B244 met the primary endpoint of a greater proportion of patients who achieved a ≥2-point reduction in Investigator’s Global Assessment (IGA) score of acne severity from baseline to week 12 vs. vehicle controls (p=0.03) in the Phase IIb portion of a Phase IIb/III trial to treat adults with mild to moderate acne vulgaris. The double-blind, U.S. trial enrolled 358 patients to receive placebo or twice-daily topical B244 for 12 weeks.

AOBiome said a second primary endpoint evaluating the reduction in inflammatory lesion count from baseline to week 12 “showed a trend” favoring B244 that reached significance compared to vehicle in the trial’s per protocol (PP) population (p=0.028). B244 was well tolerated...